Atai life sciences announces dosing of first patient in part 2 of beckley psytech's phase 2a study exploring bpl-003 adjunctive to ssris in patients with treatment resistant depression

New york and berlin, april 24, 2024 (globe newswire) -- atai life sciences (nasdaq: atai) (“atai” or “company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the first patient has been dosed in part 2 of beckley psytech's phase 2a study, evaluating bpl-003 (intranasal 5-meo-dmt) in patients living with treatment resistant depression (trd).
ATAI Ratings Summary
ATAI Quant Ranking